|
|
Kyverna Therapeutics Inc (NASDAQ: KYTX) |
|
|
|
| |
Kyverna Therapeutics Inc 's Leverage Ratio
KYTX's quarterly Leverage Ratio and Total Liabilities, Equity growth
In Spite of the repayements of liabilities of -3.71%, in Q1 2025 ,Leverage Ratio deteriorated to 0.16 reached a new all-time high.
Within Biotechnology & Pharmaceuticals industry in the first quarter 2025, 21 other companies have achieved lower Leverage Ratio than Kyverna Therapeutics Inc in the Q1 2025. While Leverage Ratio total ranking has improved so far in the first quarter 2025 to 296, from total ranking in the fourth quarter 2024 at 307 .
Explain Leverage Ratio?
How much Total Liabilitiess KYTX´s has?
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| KYTX Leverage Ratio |
(Mar 31 2025)
Q1 |
(Dec 31 2024)
Q4 |
(Sep 30 2024)
Q3 |
(Jun 30 2024)
Q2 |
(Mar 31 2024)
Q1 |
| Y / Y Equity Change |
-37.95 % |
- |
- |
- |
- |
| Y / Y Total Liabilities Change |
26.39 % |
- |
- |
- |
- |
| Leverage Ratio MRQ |
0.16 |
0.14 |
0.12 |
0.09 |
0.08 |
| KYTX's Total
Ranking |
# 296 |
# 307 |
# 239 |
# 159 |
# 0 |
| Seq. Equity Change |
-15.97 % |
-11.93 % |
-9.23 % |
-7.61 % |
- |
| Seq. Total Liabilities Change |
-3.71 % |
4.31 % |
23.23 % |
2.12 % |
- |
| Leverage Ratio first quarter 2025 Company Ranking |
| Within: |
No. |
| Biotechnology & Pharmaceuticals Industry |
# 22 |
| Healthcare Sector |
# 154 |
| Overall Market |
# 296 |
| Leverage Ratio Statistics |
| High |
Average |
Low |
| 0.16 |
0.12 |
0.08 |
| (Mar 31 2025) |
|
(Mar 31 2024) |
Cumulative Kyverna Therapeutics Inc 's Leverage Ratio
KYTX's Leverage Ratio for the trailling 12 Months
KYTX Leverage Ratio |
(Mar 31 2025)
12 Months |
(Dec 31 2024)
12 Months |
(Sep 30 2024)
12 Months |
(Jun 30 2024)
12 Months |
(Mar 31 2024)
12 Months |
| Y / Y Equity TTM Growth |
212.15 % |
- |
- |
- |
- |
| Y / Y Total Liabilities TTM Growth |
385.62 % |
- |
- |
- |
- |
| Leverage Ratio TTM |
0.12 |
0.11 |
0.1 |
0.08 |
0.08 |
| Total Ranking TTM |
# 1
| # 1
| # 147
| # 118
| # 0
|
| Seq. Equity TTM Growth |
-10.84 % |
26.73 % |
43.59 % |
92.39 % |
- |
| Seq. Total Liabilities TTM Growth |
5.75 % |
40.02 % |
62.26 % |
102.12 % |
- |
News about Kyverna Therapeutics Inc Leverage Ratio |
|
In an urgent alert, the Rosen Law Firm, a highly recognized entity in the field of investor rights, has prompted investors of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) to secure legal counsel ahead of a critical February 7, 2025 deadline concerning a securities class action. This action pertains to investors who acquired common shares during the company?s initial public offering (IPO) conducted on February 8, 2024.The IPO, which raised significant capital for Kyverna Therapeutics, marked a pivotal moment for the company, positioning it as a player in the biotechnology sector with an emphasis on innovative drug therapies. However, the circumstances surrounding the IPO have drawn scrutiny, leading to the announcement of potential legal repercussions for Kyverna and its stakeholders.
|
|
Falling Under the Microscope: The Kyverna Therapeutics Class Action LawsuitIn an unfolding drama that intertwines the pharmaceutical world with the legal arena, Kyverna Therapeutics, Inc. known for its pioneering efforts in immune-mediated diseases, finds itself at the epicenter of a burgeoning class action lawsuit. The lawsuit, filed by the esteemed law firm Bragar Eagel and Squire, P.C. represents a crucial moment in the company s narrative, a moment that merits close scrutiny by investors and industry observers alike. The Ripple of a Legal WaveOn December 11, 2024, Bragar Eagel and Squire announced the class action, filed in the United States District Court for the Northern District of California. The lawsuit encompasses all individuals and entities that purchased or acquired Kyverna securities, linked to the company s Initial Public Offering (IPO) executed on February 8, 2024. This legal motion echoes a familiar refrain in the stock market, where emerging pharmaceutical firms must navigate both scientific challenges and the stringent demands of transparency in their financial dealings.
|
On the trailing twelve months basis Despite of the repayements of liabilities of -3.71% in the trailing twelve months ending in Q1 2025, Leverage Ratio improved to 0.12, below Kyverna Therapeutics Inc 's average Leverage Ratio. Leverage Ratio is the average cumulative value over the last four quarters.
Among companies in the Biotechnology & Pharmaceuticals industry KYTX recorded the lowest Leverage Ratio. While total ranking remained unchanged compared to previous 12 month period at no. 1.
Explain Leverage Ratio?
How much Total Liabilitiess KYTX´s has?
| TTM Leverage Ratio Company Ranking |
| Within: |
No. |
| Within the Biotechnology & Pharmaceuticals Industry |
# 0 |
| Healthcare Sector |
# 0 |
| Within the Market |
# 1 |
| trailing twelve months Leverage Ratio Statistics |
| High |
Average |
Low |
| 0.12 |
0.12 |
0.11 | | (Mar 31 2025) |
|
(Dec 31 2024) |
|
